Pay in 4 interest-free payments of $13.75 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis
(2012) Nature 485(7396):62-8
higher doses than those required for anticonvulsant efficacy of the drugs were needed for activity in the reversal-learning model
Rodriguez AL
48 hours) and VS-5584 treatment causes significant induction of cell death in human pancreatic cancer (HPAC) cells in PDAC cell lines BxPC-3
CC-930 - CAS# 899805-25-5 Catalog No.:M6544-10 TOPK inhibitor induces complete tumorCC 930, also known as Tanzisertib, CAS No. 899805 25 5, is a potent, selective, and orally active JNK inhibitor with potential antifibrotic activity. CC 930 entered Phase I clinical trials. Tanzisertib may have potential use for prevention and treatment of dermal fibrosis. Selective inhibition of JNK by CC 930 exerted potent antifibrotic effects in vitro and in different models in vivo. JNK might thus be a novel molecular target for the treatment of
US$ 38.00
US$ 178.00
US$ 98.00
US$ 75.00
US$ 125.00
US$ 75.00
US$ 125.00
US$ 142.00
US$ 85.00
US$ 125.00
US$ 38.00